Toronto: Taking tissue engineering to a whole new level researchers have developed a new technology to build model versions of both heart and liver tissues that function like the real thing.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Growing realistic human tissues outside the body, the "person-on-a-chip" technology, called AngioChip, could offer a powerful platform for discovering and testing new drugs, and researchers believe that the engineered tissues could eventually be used to repair or replace damaged organs.

"It is a fully three-dimensional structure complete with internal blood vessels," said one of the researchers Milica Radisic, professor at the University of Toronto in Canada.

"It behaves just like vasculature, and around it there is a lattice for other cells to attach and grow," Radisic noted.

The work was published in the journal Nature Materials.

Out of POMaC, a polymer that is both biodegradable and biocompatible, the researchers built a scaffold for individual cells to grow.

The scaffold is built out of a series of thin layers, stamped with a pattern of channels that are each about 50 to 100 micrometres wide. 

The layers, which resemble the computer microchips, are then stacked into a 3D structure of synthetic blood vessels. As each layer is added, UV (ultraviolet) light is used to cross-link the polymer and bond it to the layer below.

When the structure is finished, it is bathed in a liquid containing living cells. The cells quickly attach to the inside and outside of the channels and begin growing just as they would in the human body.

"Our liver actually produced urea and metabolized drugs," Radisic pointed out. 

The researchers believe that AngioChip could enable drug companies to detect dangerous side effects and interactions between organ compartments long before their products reach the market, saving countless lives. 

In future, Radisic envisions her lab-grown tissues being implanted into the body to repair organs damaged by disease.

"It really is multifunctional, and solves many problems in the tissue engineering space," Radisic said. 

"It's truly next generation," she noted.